Pulmonary Arterial Hypertension in Patients Infected with the Human Immunodeficiency Virus.

Autor:	Hon SM; Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, 800 Washington Street, Box 257, Boston, MA 02111, USA. Electronic address: shon@tuftsmedicalcenter.org., Alpizar-Rivas RM; Division of Infectious Diseases, University of Rochester Medical Center, 601 Elmwood Avenue, Box 689, Rochester, NY 14642, USA., Farber HW; Division of Pulmonary, Critical Care, and Sleep Medicine, Tufts Medical Center, 800 Washington Street, Box 257, Boston, MA 02111, USA.
Jazyk:	angličtina
Zdroj:	Cardiology clinics [Cardiol Clin] 2022 Feb; Vol. 40 (1), pp. 45-54.
DOI:	10.1016/j.ccl.2021.08.004
Abstrakt:	It is important to recognize and treat human immunodeficiency virus-associated pulmonary arterial hypertension (HIV-PAH) because of the associated morbidity and mortality. With the introduction of antiretroviral therapies (ART), improved survival has changed the focus of treatment management from immunodeficiency-related opportunistic infections to chronic cardiovascular complications, including HIV-PAH. The 2018 6th World Symposium of Pulmonary Hypertension recommended a revised definition of PAH that might result in a greater number of patients with HIV-PAH; however, the implication of this change is not yet clear. Here, we review the current literature on the diagnosis, management, and outcomes of patients with HIV-PAH. Competing Interests: Disclosure The authors have nothing to disclose. (Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu